GLAXO financials GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited (GLAXO) has 8 financial years on file, from the year to 31 Dec 2018. The latest, the year to 31 Dec 2025 earned Rs 31.48 a share on sales of Rs 65.9 bn. 5 quarters are listed below the years.
Results by financial year
Company accounts as filed. Earnings per share are on today’s share count where a split or bonus issue came later. Years to 31 December. 4 of the last 5 years and 5 of the last 8 quarters.
Earnings per share by financial year
| Year | Earnings per share (Rs) | Sales | Gross margin | Net profit as a share of sales | Change in earnings per share on the year before |
|---|---|---|---|---|---|
| Year to 31 Dec 2025 | 31.48 | Rs 65.9 bn | 37.0% | 15.2% | +53.4% |
| Year to 31 Dec 2024 | 20.52 | Rs 61.2 bn | 25.2% | 10.7% | +1,121.4% |
| Year to 31 Dec 2023 | 1.68 | Rs 49.7 bn | 7.1% | 1.1% | -78.3% |
| Year to 31 Dec 2022 | 7.73 | Rs 41.8 bn | 17.4% | 5.9% | — |
Results by quarter
5 of the last 8 quarters. The fourth quarter is filed only inside the annual accounts.
| Quarter | Earnings per share (Rs) | Sales | Profit after tax | Net profit as a share of sales | Change on the same quarter a year before |
|---|---|---|---|---|---|
| Quarter to 30 Sep 2026 | 8.20 | Rs 16.6 bn | Rs 2.6 bn | 15.7% | +28.1% |
| Quarter to 30 Jun 2026 | 6.19 | Rs 14.5 bn | Rs 2.0 bn | 13.6% | -4.8% |
| Quarter to 31 Mar 2026 | 8.20 | Rs 17.0 bn | Rs 2.6 bn | 15.3% | — |
| Quarter to 30 Sep 2025 | 6.40 | Rs 14.2 bn | Rs 2.0 bn | 14.4% | — |
| Quarter to 30 Jun 2025 | 6.50 | Rs 14.7 bn | Rs 2.1 bn | 14.1% | — |
Annual report figures: income and balance sheet
From each annual report. A blank is a line this page does not show for that year.
| Year | Revenue | Gross profit | Profit after tax | Total assets | Equity | Liabilities | Return on equity | Current ratio | Basis |
|---|---|---|---|---|---|---|---|---|---|
| Year to 31 Dec 2024 | — | — | — | Rs 45.1 bn | Rs 28.3 bn | Rs 16.8 bn | — | 2.06 | unknown |
| Year to 31 Dec 2022 | — | — | — | Rs 35.5 bn | Rs 21.1 bn | Rs 14.5 bn | — | 1.82 | unknown |
| Year to 31 Dec 2021 | — | — | — | Rs 30.5 bn | Rs 21.0 bn | Rs 9.5 bn | — | — | unknown |
| Year to 31 Dec 2020 | — | — | — | Rs 26.1 bn | Rs 17.5 bn | Rs 8.6 bn | — | 2.02 | unknown |
| Year to 31 Dec 2019 | — | — | — | Rs 23.2 bn | Rs 16.1 bn | Rs 7.1 bn | — | 2.04 | unknown |
| Year to 31 Dec 2018 | — | — | — | Rs 22.2 bn | Rs 15.4 bn | Rs 6.8 bn | — | — | unknown |
Source: annual report, page 98.
Ratios from the latest annual report
- Book value a share
- Rs 88.79
- Price to book value
- 3.79 times
- Current ratio
- 2.06
- Debt to equity
- 0.59
- Equity as a share of assets
- 62.8%
As of 31 Dec 2024.
Cash flow
Where the cash came from and went
| Operating cash flow | Rs 8.7 bn |
| Capital spending | Rs -2.6 bn |
| Free cashworked out: operating cash flow less capital spending | Rs 6.1 bn |
| Dividends paid | Rs -4.7 bn |
| Change in cash | Rs 2.1 bn |
| Cash at the start of the year | Rs 6.5 bn |
| Cash at the end of the year | Rs 8.6 bn |
Accounts, year to 31 Dec 2025 · filed annual report, page 87The report does not say whether these are group accounts or the company’s own.
More on GLAXO
- GLAXO share price and overview
- GLAXO dividend history
- Pharmaceuticals sector
- HALEON financials · Haleon Pakistan Limited
- HINOON financials · Highnoon Laboratories Limited
- ABOT financials · Abbott Laboratories (Pakistan) Limited
- SEARL financials · The Searle Company Limited
- AGP financials · AGP Limited
Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .